The Hormone Conversation Women Weren't Supposed to Have
Testosterone has long been framed as a male hormone. Emerging research suggests that reframing may be one of the most consequential shifts in women's health in a generation.
For decades, the conversation about testosterone has been told almost entirely in one gender. Men's clinics, men's symptoms, men's decline curves — the cultural and clinical narrative built a wall around the molecule and labeled it accordingly. Women, meanwhile, were handed a narrower vocabulary: estrogen, progesterone, the menopausal transition. Important conversations, certainly. But incomplete ones.
What that framing missed is something researchers and clinicians are now taking seriously: testosterone is not a male hormone. It is a human hormone. And in women, its decline — which begins earlier, moves more quietly, and receives far less attention — may account for a meaningful portion of the fatigue, cognitive fog, diminished motivation, and loss of physical vitality that millions of women are told is simply the cost of getting older.
It isn't.
What Testosterone Actually Does in Women
Women produce testosterone in the ovaries and adrenal glands throughout their lives, and while the concentrations are lower than in men, the physiological role is no less significant. Testosterone in women contributes to skeletal muscle maintenance, bone density, libido, mood regulation, and cognitive sharpness. It also appears to play a role in cardiovascular health and metabolic function — areas where women's risk profiles shift considerably in midlife.
The decline, however, starts long before menopause. Testosterone levels in women begin falling in the late 20s and continue on a gradual trajectory through the 30s and 40s. By the time a woman reaches her mid-40s, her testosterone levels may be half of what they were in her early 20s. This is not a dramatic event with a clear clinical marker — there is no testosterone equivalent of the menopausal transition to anchor the experience. The decline is diffuse, subtle, and easy to attribute to everything else: stress, sleep deprivation, a demanding life.
"The absence of a dramatic clinical threshold doesn't mean the absence of a meaningful biological change."
That quiet erosion is precisely what makes it so easy to miss — and so worth looking for.
What the Research Is Beginning to Clarify
The evidence base around testosterone therapy in women has lagged behind the clinical intuition of practitioners who have been working in this space for years. But that gap is narrowing. A 2022 review in the Journal of Personalized Medicine found that testosterone therapy in women was associated with improvements in sexual function, mood, energy, and cognitive clarity, with a favorable safety profile when appropriately dosed and monitored (Donovitz, 2022). More recently, a 2025 position statement from the Latin American Association of Gynecological Endocrinology offered a formal clinical framework for androgen therapy in midlife and older women, reflecting a growing consensus that this is not a fringe conversation — it is a necessary one (Pilnik et al., 2025).
The recurring themes across this research are worth noting:
- Suboptimal testosterone in women is associated with fatigue, reduced muscle mass, low libido, and diminished sense of well-being
- Physiological restoration — rather than supraphysiological dosing — appears to be the relevant therapeutic target
- Monitoring matters: baseline testing, individualized dosing, and follow-up labs are consistently emphasized as central to safe and effective outcomes
- The risk of adverse effects, when therapy is appropriately managed, appears to be low
None of this means testosterone is a universal solution, or that every woman experiencing fatigue should seek hormone therapy. The endocrine system is too interconnected, and human biology too individual, for blanket prescriptions. But it does mean that the question deserves to be asked — and tested for — with the same rigor and openness applied to any other addressable root cause.
The Framing Problem Worth Solving
There is something worth examining in the cultural reluctance to discuss testosterone as a women's health issue. Part of it is historical: the research simply wasn't done, because the clinical establishment didn't ask the question with sufficient seriousness. Part of it is linguistic: a hormone named in cultural imagination as masculine carries assumptions that die slowly. And part of it is systemic: a healthcare model oriented around crisis and diagnosis, rather than optimization and prevention, is not designed to catch a gradual decline in a molecule that falls outside the conventional checklist.
What is changing — slowly, measurably — is the willingness of both researchers and patients to push past that framing. Women in their 30s, 40s, and 50s are increasingly arriving at conversations about their health with more detailed questions, more self-awareness, and less tolerance for being told that what they are experiencing is simply aging. They are right to push. The science, it turns out, has been waiting for the conversation to catch up.
Hormonal health in women is not a footnote to the broader story of longevity. It is one of its central chapters — and for too long, it has been written in pencil, tentatively, when it deserved ink.
